Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Afatinib MeSH Descriptor Data 2025


MeSH Heading
Afatinib
Tree Number(s)
D02.065.132
D03.633.100.786.188
Unique ID
D000077716
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000077716
Scope Note
A quinazoline and butenamide derivative that acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER.
Entry Term(s)
(2E)-N-(4-(3-Chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide
Afatinib Dimaleate
Afatinib Maleate
BIBW 2992
BIBW-2992
BIBW-2992-MA2
BIBW-2992MA2
BIBW2992
BIBW2992 MA2
Gilotrif
Pharm Action
Antineoplastic Agents
Tyrosine Kinase Inhibitors
Registry Numbers
41UD74L59M
0
V1T5K7RZ0B
Related Numbers
850140-72-6
V1T5K7RZ0B
CAS Type 1 Name
2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-, (2E)-
Public MeSH Note
2019; AFATINIB was indexed under QUINAZOLINES 2007-2018
History Note
2019 (2007)
Date Established
2019/01/01
Date of Entry
2018/07/09
Revision Date
2023/08/04
Afatinib Preferred
BIBW 2992 Narrower
Gilotrif Narrower
Afatinib Dimaleate Narrower
BIBW-2992-MA2 Narrower
Afatinib Maleate Narrower
page delivered in 0.173s